Answers are grounded in this paper and cite their sources.
Systematic review and meta-analysis reveals JCV seroprevalence patterns indicating widespread distribution in healthy populations, implying future treatment implications.
JCV seroprevalence starts high in early infant age, descends in late childhood/early adulthood, and starts to rise again towards older age, most probably, by viral reactivation due to immune senescence. The overall findings support the hypothesis that JCV is ubiquitous in the healthy human population, and not just diseased populations, which may have implications with JCV treatment, screening, and vaccine development. To the best of our knowledge, this is the first meta-analysis conducted on JCV seropositivity in healthy populations.
No takes yet. Share an insight, caveat, or question.
Kimla et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: